Search - tctmd.com

Displaying 1 - 20 of 54

Sort: Relevancy | Date

News Daily News

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Yael L. Maxwell

December 19, 2018

News Conference News WCC 2018

CVD, Other Noncommunicable Diseases Hit Lower-Income Countries With Heavy Financial Burden

Todd Neale

December 06, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Daily News

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

Shelley Wood

November 23, 2018

News Daily News

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Michael O'Riordan

November 23, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

Shelley Wood

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Michael O'Riordan

October 30, 2018

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Daily News

CAC Scoring Is Predictive of Risk Across Races and Ethnicities

L.A. McKeown

October 16, 2018

News Daily News

Beta-blocker Use in Pregnancy Doesn’t Up Birth Defect Risk, Study Suggests

Caitlin E. Cox

October 15, 2018

Advertisement

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

CVD, Other Noncommunicable Diseases Hit Lower-Income Countries With Heavy Financial Burden

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

CAC Scoring Is Predictive of Risk Across Races and Ethnicities

Beta-blocker Use in Pregnancy Doesn’t Up Birth Defect Risk, Study Suggests

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content